Regenxbio Retained Earnings from 2010 to 2024

RGNX Stock

USD 9.18 0.45 4.67%

Regenxbio Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Regenxbio retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2014-12-31

Previous Quarter

-821.4 M

Current Value

-881 M

Quarterly Volatility

236.8 M

Yuan Drop

Covid

Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.2 M, Interest Expense of 6.5 M or Selling General Administrative of 47.8 M, as well as many indicators such as Price To Sales Ratio of 8.26, Dividend Yield of 0.0 or PTB Ratio of 2.64. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.

Check out the analysis of Regenxbio Correlation against competitors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Latest Regenxbio's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Regenxbio over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Regenxbio's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regenxbio's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (705.05 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Regenxbio Retained Earnings Regression Statistics

	Arithmetic Mean	(200,635,510)
	Coefficient Of Variation	(114.53)
	Mean Deviation	173,723,281
	Median	(114,587,000)
	Standard Deviation	229,794,195
	Sample Variance	52805.4T
	Range	680.2M
	R-Value	(0.85)
	Mean Square Error	15793.2T
	R-Squared	0.72
	Significance	0.00006
	Slope	(43,669,384)
	Total Sum of Squares	739275.2T

Regenxbio Retained Earnings History

	2024	-669.8 M
	2023	-705 M
	2022	-441.6 M
	2021	-161.2 M
	2020	-289.1 M
	2019	-177.8 M
	2018	-83 M

Other Fundumenentals of Regenxbio

Retained Earnings Total Equity

Regenxbio Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Short Term Investments	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Net Working Capital	Long Term Debt Total	Capital Stock
Total Assets		0.96	0.75	-0.58	-0.54	0.71	0.84	0.89	0.96	0.53	-0.63	0.95	0.68	0.69	0.83	-0.17	0.73	0.89	0.92	0.85	-0.17	-0.17
Total Stockholder Equity	0.96		0.82	-0.55	-0.43	0.6	0.76	0.73	0.93	0.42	-0.67	0.96	0.69	0.7	0.87	-0.13	0.64	0.81	0.94	0.82	-0.13	-0.13
Current Deferred Revenue	0.75	0.82		-0.5	-0.17	0.34	0.69	0.5	0.7	0.14	-0.59	0.74	0.5	0.6	0.79	0.13	0.38	0.6	0.76	0.59	0.13	0.13
Net Debt	-0.58	-0.55	-0.5		-0.2	0.07	-0.53	-0.51	-0.61	0.26	0.29	-0.42	0.02	-0.3	-0.59	-0.4	0.02	-0.27	-0.49	-0.68	-0.4	-0.4
Retained Earnings	-0.54	-0.43	-0.17	-0.2		-0.93	-0.55	-0.63	-0.56	-0.97	0.48	-0.6	-0.66	-0.56	-0.09	0.8	-0.89	-0.73	-0.4	-0.41	0.8	0.8
Accounts Payable	0.71	0.6	0.34	0.07	-0.93		0.64	0.77	0.68	0.95	-0.49	0.7	0.74	0.56	0.34	-0.64	0.94	0.84	0.6	0.53	-0.64	-0.64
Net Receivables	0.84	0.76	0.69	-0.53	-0.55	0.64		0.83	0.9	0.49	-0.5	0.78	0.65	0.59	0.51	-0.18	0.6	0.81	0.73	0.86	-0.18	-0.18
Total Liab	0.89	0.73	0.5	-0.51	-0.63	0.77	0.83		0.86	0.62	-0.44	0.77	0.53	0.55	0.61	-0.21	0.77	0.88	0.72	0.75	-0.21	-0.21
Total Current Assets	0.96	0.93	0.7	-0.61	-0.56	0.68	0.9	0.86		0.52	-0.67	0.92	0.72	0.74	0.69	-0.18	0.66	0.86	0.85	0.91	-0.18	-0.18
Short Term Debt	0.53	0.42	0.14	0.26	-0.97	0.95	0.49	0.62	0.52		-0.48	0.57	0.65	0.46	0.14	-0.79	0.91	0.71	0.42	0.37	-0.79	-0.79
Common Stock	-0.63	-0.67	-0.59	0.29	0.48	-0.49	-0.5	-0.44	-0.67	-0.48		-0.69	-0.54	-0.69	-0.45	0.22	-0.44	-0.53	-0.49	-0.49	0.22	0.22
Net Tangible Assets	0.95	0.96	0.74	-0.42	-0.6	0.7	0.78	0.77	0.92	0.57	-0.69		0.76	0.74	0.78	-0.27	0.75	0.91	0.88	0.75	-0.27	-0.27
Short Term Investments	0.68	0.69	0.5	0.02	-0.66	0.74	0.65	0.53	0.72	0.65	-0.54	0.76		0.68	0.36	-0.3	0.63	0.8	0.62	0.55	-0.3	-0.3
Deferred Long Term Liab	0.69	0.7	0.6	-0.3	-0.56	0.56	0.59	0.55	0.74	0.46	-0.69	0.74	0.68		0.43	-0.18	0.51	0.68	0.55	0.55	-0.18	-0.18
Long Term Investments	0.83	0.87	0.79	-0.59	-0.09	0.34	0.51	0.61	0.69	0.14	-0.45	0.78	0.36	0.43		0.14	0.46	0.61	0.85	0.58	0.14	0.14
Short Long Term Debt	-0.17	-0.13	0.13	-0.4	0.8	-0.64	-0.18	-0.21	-0.18	-0.79	0.22	-0.27	-0.3	-0.18	0.14		-0.69	-0.32	-0.22	-0.2	1.0	1.0
Property Plant Equipment	0.73	0.64	0.38	0.02	-0.89	0.94	0.6	0.77	0.66	0.91	-0.44	0.75	0.63	0.51	0.46	-0.69		0.85	0.68	0.52	-0.69	-0.69
Capital Surpluse	0.89	0.81	0.6	-0.27	-0.73	0.84	0.81	0.88	0.86	0.71	-0.53	0.91	0.8	0.68	0.61	-0.32	0.85		0.77	0.67	-0.32	-0.32
Net Invested Capital	0.92	0.94	0.76	-0.49	-0.4	0.6	0.73	0.72	0.85	0.42	-0.49	0.88	0.62	0.55	0.85	-0.22	0.68	0.77		0.84	-0.22	-0.22
Net Working Capital	0.85	0.82	0.59	-0.68	-0.41	0.53	0.86	0.75	0.91	0.37	-0.49	0.75	0.55	0.55	0.58	-0.2	0.52	0.67	0.84		-0.2	-0.2
Long Term Debt Total	-0.17	-0.13	0.13	-0.4	0.8	-0.64	-0.18	-0.21	-0.18	-0.79	0.22	-0.27	-0.3	-0.18	0.14	1.0	-0.69	-0.32	-0.22	-0.2		1.0
Capital Stock	-0.17	-0.13	0.13	-0.4	0.8	-0.64	-0.18	-0.21	-0.18	-0.79	0.22	-0.27	-0.3	-0.18	0.14	1.0	-0.69	-0.32	-0.22	-0.2	1.0

Click cells to compare fundamentals

About Regenxbio Financial Statements

Regenxbio investors use historical fundamental indicators, such as Regenxbio's Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-705 M	-669.8 M
Retained Earnings Total Equity	-145.1 M	-152.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC